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Abstract.  GP85 is one of the most common hemo- 
poietic isoforms of the cell adhesion molecule, 
CD44.  CD44(GP85) is known to contain at least one 
ankyrin-binding site within its 70 aa cytoplasmic do- 
main and to bind hyaluronic acid (HA) with its ex- 
tracellular domain. In this study we have mapped the 
ankyrin-binding domain of CD44(GP85) by deleting 
various portions of the cytoplasmic region followed by 
expression of these truncated cDNAs in COS cells. 
The results of these experiments indicate that the 
ankyrin-binding domain resides between amino acids 
305  and 355.  Biochemical analyses, using competition 
binding assays and a synthetic peptide (NGGNGT- 
VEDRKPSEL) containing 15 aa between aa 305  and 
aa 320,  support the conclusion that this region is re- 
quired for ankryin binding. Furthermore, we have 
constructed a fusion protein in which this  15 aa 
sequence of CD44(GP85) is transplanted onto an- 
other transmembrane protein which does not bind 
ankyrin. Our results show that this fusion protein ac- 
quires the ability to bind ankyrin confirming that the 
sequence (~NGGNGTVEDRKPSE32°L) is a critical 
part of the ankryin-binding domain of CD44(GP85). 
In addition, we have demonstrated that deletion of this 
15 aa ankyrin-binding sequence from CD44(GP85) 
results in a drastic reduction (>190%) of HA-binding 
and HA-mediated cell adhesion. These findings 
strongly suggest that ankyrin binding to the cytoplas- 
mic domain of CIM4(GP85) plays a pivotal role in 
regulating hyaluronic acid-mediated cell-cell and 
cell-extracellular matrix interactions. 
T 
HE 85-kD mouse lymphocyte transmembrane glyco- 
protein, GP85 (also known as Pgp-1), is a well known 
T-cell  differentiation  antigen  (66).  The  cDNA  se- 
quence data indicate that mouse GP85 shares 72 % aa homol- 
ogy with human lymphocyte homing receptor CD44 (also 
called GP90  Hc~ antigen,  ECMR HI, and homing cellular 
adhesion molecule [H-CAM] 1) (6,  18,  19,  34,  35,  51, 69, 
70).  GP85  is one of the most common isoforms of CD44 
found in  all  hemopoietic cells including  T-cells,  B-cells, 
macrophages,  and granulocytes (33, 42, 66).  CIM4(GP85) 
has also been detected in many other cell types such as 
fibroblasts,  epithelial  ceils,  and more recently endothelial 
cells (14, 17, 52). To date at least 15 isoforms of CD44 have 
been identified.  Some of these isoforms result from exten- 
sive, alternative  exon splicing events (55, 57, 65). 
CD44(GP85)  has been shown to mediate the binding be- 
tween lymphocytes and capillary high endothelial  venules 
(HEV) during lymphocyte  homing into lymphoid organs (6, 
52).  In addition,  CD44(GP85)  is involved in T- and B-cell 
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adhesion, cell aggregation  and proliferation  (30, 59).  Al- 
though the functional role of CIM4 is not fully understood, 
certain isoforms  have been implicated  recently in tumor 
metastasis (1, 2, 29, 31, 60). 
The  extracellular  matrix  component,  hyaluronic  acid 
(HA), is one of the ligands specifically recognized by CD44- 
(GP85)  (19, 32,  40,  54,  58,  67).  CD44(GP85)  mediates 
HA-dependent  cell adhesion  in many cell types including 
leukocytes,  fibroblasts,  and macrophages (67).  HA-depen- 
dent cell adhesion plays an important role in mediating (a) 
interaction  between stromal cells  and lymphoid precursor 
cells in the bone marrow, (b) cell migration, and, (c) most 
likely, T-cell activation and B-cell maturation (19, 22, 30, 48, 
63, 67). Recent studies suggest that certain factors,  such as 
protein kinase C (40) and the cytoplasmic domain of CD44- 
(GP85)  (41), may be important for the expression  of HA- 
binding  site(s).  However,  the molecular mechanisms in- 
volved in regulating  the surface expression  of HA-binding 
site(s) are not known. 
Previously, we have demonstrated that the cytoplasmic  do- 
main of CD44(GP85) (,x,70 aa long) that is conserved >190% 
in most of the CD44 isoforms, is involved in ankyrin binding 
(16, 37). The ankyrin-binding  site(s) is expressed at a very 
early stage in the biosynthesis  of CD44(GP85)  (43).  Fur- 
thermore, the binding interaction between CD44(GP85) and 
ankyrin is highly specific and regulated by several factors in- 
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palmityolation  (12),  and GTP binding  (45).  The  fact that 
ankyrin preferentially accumulates  underneath CD44(GP- 
85)  capped  structures  suggests  that the  formation  of an 
ankyrin-CD44(GP85)  complex is related to ligand-induced 
lymphocyte activation (16, 37). However, the physiological 
significance  of this close association  between ankyrin and 
CD44(GP85) during HA-mediated cell-matrix adhesion is 
not fully understood. 
In this manuscript, we have mapped the ankyrin-binding 
domain of CD44(GP85) by constructing several cytoplasmic 
deletion mutants and expressing them in COS ceils. Our data 
indicate that deletion of a particular 15 aa sequence  in the 
cytoplasmic  domain  of CD44(GP85) leads  to a complete 
loss of ankyrin binding. Most interestingly, however, the de- 
letion of ankyrin-binding  domain  also  abolishes  the HA- 
binding/HA-dependent  cell  adhesion  capability  of CD44- 
(GP85) without significantly affecting its overall cell surface 
expression.  Therefore,  binding  of ankyrin to cytoplasmic 
domain of CD44(GP85) may be critically important for the 
proper surface expression of HA-mediated adhesion in cells 
containing CIM4(GP85). 
Materials and Methods 
Reagents 
Rc/CMV  plasmid containing the  full-length  mouse CD44(GP85/Pgp-1) 
eDNA clone was kindly provided by Dr. Eugene Butcher (Stanford Univer- 
sity, CA [70]).  Mouse CD45(B 200; 64) eDNA was a gift from Dr.  Ian 
Trowbridge (Salk Institute, La Julia, CA). pcDNA I was obtained from In- 
Vitrogen. An adaptor containing termination codons in all of the three pos- 
sible reading frames with a Not I cohesive end was synthesized by the DNA 
facility (University of Miami, Miami, FL). Erythrocyte ankyrin, spectrin, 
pig brain fodrin, and 3H-HA were prepared as described previously (5, 28, 
68). Rat anti-CD44(GP85) monoclonal antibody IM7, which recognizes an 
epitope in the extracellular domain of CD44(GP85), and rat anti-CD45 
monoclonal antibody I3/2.3 (kindly provided by Dr. Robert Hyman, Salk 
Institute) were purified from the hybridoma culture supernatant by sequen- 
tial ammonium sulfate fractionatiun and DEAE-eellulose chromatography. 
Anti-CIM4(GP85) antibody, anti-CD45 antibody, ankyrin, and WGA (Sig- 
ma Chem. Co., St. Louis, MO) were coupled to CNBr-activated  Sepharose 
beads (Pharmacia LKB Biotechnology,  Piseataway,  N J) according to the 
manufacturer's procedure.  The region I and scramble peptides (described 
below)  were  synthesized  by  Dr.  Eric  Smith  (University  of  Miami, 
Miami, FL). 
Cell Culture 
COS-7 cells were obtained from Amer. Type Culture Collection (Rockville, 
MD) and grown routinely in DMEM containing 10% FBS,  1% gintamine, 
1% penicillin and 1% streptomycin.  Mouse T-lymphoma BW5147 cells were 
cultured in DMEM containing 10% horse serum, 1% penicillin, and 1% 
streptomycin. 
Protein Iodination 
Ankyrin, fodrin, spectrin, anti-CD44(GP85) monoclonal antibody, purified 
lymphoma CD44(GP85), and surface  proteins of COS-7 cells were iodi- 
hated using IodoGen as described (26). 
Deletion Mutagenesis 
A 1.3-kb eDNA containing the entire mouse CD44(GP85) coding sequence 
cloned into pRc/CMV (InVitrogen Co.) was digested with Pst I, Sst I, Bcl 
I, and Tha I to generate mutants CD44(GPg5)A355, CD44(GPg5)A320, 
CD44(GP85)A305,  and CD44(GP85)AA292.  The 3' overhanging  ends 
resulting from Psi I and Sst I digestions were blunt ended by I"4 DNA poly- 
merase. Tha I digestion leaves blunt ended DNA fragments.  These blunt 
ended fragments (Pst I, Sst I, and Tha I) were ligated to a synthetic Not I 
adaptor containing stop codons in all of the three possible reading frames. 
The DNA fragments were then digested with Hind 1II; the deleted CD44- 
(GP85)  inserts were gel isolated and ligated  into Hind Hi-Not I digested 
pcDNA I (InVitrogen Co.) for expression into COS cells.  Bcl I digested 
DNA was further cut with Hind IlI without blunt ending and ligated directly 
into Hind I~-Baml-II digested pcDNA I to generate the CD44(GPgS)A305 
mutant construct. The full length 1.3-kb CD(GP85) construct was also 
recloned into pcDNA I as a Hind HI-Not I fragment. All mutant constructs 
were characterized by restriction enzyme analyses  and DNA sequencing. 
COS Cell Transfection 
COS-7 cells were transfected  with pcDNA I plasmids containing various 
CD44(GP85) inserts using DEAE-dextran. Briefly, COS-7 cells were plated 
at a density of 2  ×  106 cells per 100-ram dish and were transfected  with 
25/~g/dish plasmid DNA. Transfected  cells were harvested after 48 h for 
analyses  of CD44(GP85) expression. 
Purification of CD44(GP83) Protein  from Transfected 
COS Cells 
Various CD44(GP85) proteins were purified from 8-10 100-ram dishes of 
COS cells transfected  with one of the CD44(GP85) constructs.  Control 
transfections consisted of  either no DNA or pcDNA I vector DNA. The pro- 
teins were purified from either unlabeled or surface  125I-iabeled  COS cells 
using non-ionic detergent Triton X-100 extraction followed by sequential 
WGA-Sepharose and anti-CD44(GP85) immunoafl~nity chromatographies, 
essentially  according to the procedure described previously  (43, 45). Pro- 
tein concentrations were determined using the protein assay reagent (Bio- 
Pad Labs., Hercules, CA).  Purity of the protein preparations was deter- 
mined by SDS-PAGE followed by silver staining and/or autoradiography. 
Binding of uSI-labeled Ankyrin to 
CD44(GP85) Proteins 
Aliquots  (10-20  ng  protein)  of  both  purified  wild-type  and  mutant 
CD44(GP85)  proteins bound  to  the  anti-CD44(GP85)  immunoaffinity 
beads were incubated in 0.5 ml of binding buffer (20 raM Tris.HCl pH 7.4, 
150 mM NaCI, 0.1% BSA and 0.05 % Triton X-100) containing various con- 
centrations (10--400 ng/ml) of 125I-labeled ankyrin (5,000 cpm/ng protein) 
at 4°C  for 5  h.  Non-specific  binding was  determined in presence of a 
50-100-fold excess of unlabeled ankyrin and also by incubating the anti- 
CD44(GP85) immunobeads alone in the presence of the same concentration 
of 125I-labeled ankyrin. After binding, the immunobeads were washed ex- 
tensively in binding buffer and the bead-bound radioactivity was counted. 
Non-specific  binding was '~20% of the total binding. 
Binding of us  I-labeled Ankyrin/Fodrin/Spectrin to 
Synthetic Region I and Scramble Peptides 
Nitrocellulose discs (l-cm diam) were coated with =1 ~g of either the region 
I (NGGNGTVEDRKPSEL) or a  scramble peptide (GRNETNPEGSGL- 
DVK) at 4oc for 16 h. After coating, the unoccupied sites on the discs were 
blocked by incubation with a solution containing 20 mM Tris.HCl pH 7.4 
and 0.3% BSA at 4°C for 2 h. The discs were then incubated with various 
concentrations (20, 40, and 80 ng/ml) of 125I-labeled ankyrin/specttin/fo- 
drin (=3,000 cpnffng) at 4°C for 2 h in 1 ml binding buffer (20 mM "Iris.  HC1 
pH 7.4, 150 mM NaCI, 0.2% BSA). After biDding~ the discs were washed 
three times in the binding buffer and the disc bound radioactivity  was esti- 
mated. The non-specific binding was determined in the presence of a 100- 
fold excess of respective unlabeled ligends and was subtracted from the total 
binding. Non-specific binding was '~30% of the total binding. As controls, 
the ligands were also incubated with uncoated nitrocellulose discs to deter- 
mine the binding observed due to  the "stickyness"  of various ligands. 
Nonspecific  binding was observed in these controls. 
Binding of WI-labeled  Lymphoma CD44(GP85) 
to Ankyrin 
CD44(GP85)  was purified from the plasma membrane preparations of 
mouse T-lymphoma  cells, by sequential WGA-Sepharose  and anti-CD44- 
(GP85) immunoaflinity chro~ographies as described previously (43, 45). 
125I-labeled CD44(GP85) (=0.32 nM protein, 1.5  ×  lif  t cpm/ng) was in- 
cubated with 30/~1  of ankyrin conjugated to Sepharose beads (=0.75/~g pro- 
tein) in 0.5 ml of the binding buffer (described above). The binding was car- 
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of unlabeled competing synthetic region I peptide (NGGNGTVEDRKP- 
SEL) or the scramble peptide (GRNETNPEGSGLDVK) at 4°C for 5 h un- 
der equilibrium conditions. Equilibrium conditions were determined by 
performing time course (e.g., 1-10 h) of the binding studies. After binding, 
the beads were washed in the binding buffer and the bead bound radioactiv- 
ity was determined. Nun-specific  binding was determined in the presence 
of either a  100-fold excess of unlabeled ankyrin or using BSA-conjngated 
Sepharose beads. The non-specific binding was 20-30 % of the total binding 
and was subtracted from the total binding. 
Binding of l~l-labeled Band 3 Cytoplasmic Domain 
Fragment to Ankyrin 
The human band 3 protein cytoplasmic domain fragment (=43 kD) that 
binds ankyrin, was isolated from the erythrocyte ghost as described previ- 
ously (5). The band 3 protein fragment was 125I-labeled  to a specific activ- 
ity of 6  x  104 cpm/ng. The binding of the 125I-labeled band 3 fragment 
(=0.5 nM) to ankyrin in the presence or absence of region I or the scramble 
peptides was carried out as described above. 
Construction and Expression of CD45A826/CD44 
(Reg. I) Fusion Protein 
The mouse CD45(B200) eDNA cloned in pcDNA I was partially digested 
with Kpn I, followed by complete digestion with Xho I. An oligonucleotide 
adaptor (5'CAAC  GG~~CAG TGGAAGACAC,  GAAACC CAG- 
TGAGCTCTAA3~ and its complementary strand were synthesized by DNA 
facility,  University of Miami, Miami, FL. The adaptor codes for mouse 
CD44(GP85) eDNA sequence corresponding to the 15 aa of the region I 
of the ankyrin-binding domain (69, 70), a stop codon and Kpn I and Xho I 
cohesive ends. The adaptor was annealed to its complementary strand and 
cloned into Kpn I-Xho I digested CD45(B200)/pcDNA I plasmid. The re- 
suiting construct, CD45A826/CD44(Reg.I)  contains 826 aa of CIM5 and 
15 aa of the region I of the ankyrin-binding domain. As a control, CD45- 
(B200)/pcDNA I was digested  partially with Kpn I and completely with 
Xho I and ligated to an adaptor containing stop codon, and Kpn I and Xho 
I cohesive ends.  Both CD45A826/CD44(Reg.  I) and CD45A826 eDNA 
constructs were  confirmed by sequencing.  The CIM5A826 and CIMS- 
A826/CD44(Reg.I)  constructs were  transcribed and translated in vitro 
using the TNT coupled reticulocyte system (Promega Co., Madison, WI) 
and [35S]methionine (1,000 cpm/pmol).  The in vitro translated proteins 
were purified by rat anti-CD45  immunoaffinity  chromatography as  de- 
scribed previously  (44). The expression and purity of the protein prepara- 
tions were analyzed by SDS-PAGE followed by fluorography. As controls, 
CD44(GP85)363 and CI)44(GP85)A305 proteins were also synthesized in 
vitro and purified using anti-CD44(GP85) immunoaffinity chromatography. 
Both CIM5- and CIM4(GPg5)-related protein bound to immunoaffinity 
beads (=0.3 nM protein) were incubated with 30 ng of n5I-labeled ankyrin 
(3,000 cpm/ng) in 1 ml of the binding buffer (20 mM Tris.HC1 pH 7.4, 150 
mM NaCI, 0.1% BSA, and 0.05 % Triton X-100) at 4°C for 5 h. Non-specific 
binding was detennined in the presence of 3 pg of unlabeled ankyrin and 
was subtracted. Non-specific binding was "v20% of the total binding. Other 
controls included binding of  t25I-labeled  ankyrin to  anti-CD44(GP85) 
or anti-CIM5 immunobeads alone.  No specific  binding was observed in 
these controls. 
Immunocytochemistry 
COS cells (103 cells) were grown on coverslips and transfected with either 
various CD44(GP85) cDNAs or pcDNA I vector only as described above. 
Subsequently, cells were washed with PBS and fixed in PBS containing 2 % 
paraformaldehyde.  Fixed cells were then stained with fluorescein-labeled 
HA (21) (5 #g/rnl) at room temperature for 30 rain followed by washing with 
PBS three times. To detect nonspecific HA binding, cells were incubated 
with fluorescein-labeled  HA in the presence of  an excess amount of HA (100 
#g/ml). No labeling was observed in the control samples.  The fluorescein- 
labeled samples were excited with a Xenon 75-W bulb and examined using 
a  Zeiss inverted microscope (63×  oil immersion and epi-illumination). 
Cells were photographed with Kodak Tri-X film. 
Binding of ~Sl-labeled Anti-CD44(GP85) Antibody 
and 3H-HA to COS Cells 
COS cells (2 x  105 cells/35-mm dish) were transfected with either various 
CIM4(GP85) constructs or pcDNA I vector as described above. 48 h after 
the transfections,  culture medium was removed and the cells were washed 
in PBS containing 0.2%  BSA (binding buffer).  The cells were then in- 
cubated with various concentrations of either 125I-labeled  anfi-CD44(GP85) 
antibody (50,  100, and 200 ng/ml) or 3H-HA (0.3, 0.6, and 1.2 #g/rnl) in 
the binding buffer at room temperature or 4°C for 2 h. Nonspecific binding 
was determined in the presence of a  100-fold excess of unlabeled ligand. 
After binding, the cells were washed three times in binding buffer, and then 
solubilized in 1% SDS solution.  The solubilized cell extracts were counted 
either in a gamma counter or a liquid scintillation counter. 
Cell Adhesion Assay 
COS cells were transfected with various constructs as described above. 48 h 
after transfection, cells were  labeled with Tran[3SS]methionine (30 #Ci/ 
ml) for 2 h as described previously  (43). After labeling, cells were washed 
in PBS and incubated with PBS containing 5 mM EDTA at 37°C to obtain 
non-adherent, single cell suspensions.  1.2 x  106 cpm (=105 cells) were in- 
cubated in each well of a 24-well Coming culture plate coated with HA. 
The HA-coated  plates were prepared by incubating the culture wells with 
2 mg/ml rooster comb HA at 22°C for 16 h. HA-coated plates were rinsed 
sequentially  three times with PBS containing 2% BSA and PBS before in- 
cubating with labeled cells.  Labeled cells were incubated with HA-coated 
wells at 4°C for 60 rain. After incubation, wells were washed three times 
with PBS; the adherent cells were solubilized in PBS containing 1% SDS; 
and the well-bound radioactivity was  determined by liquid scintillation 
counting.  Non-specific  binding was  determined by including 200 ~tg/ml 
soluble HA during the incubation in the HA-coated  wells.  Non-specific 
binding was 10-15% of the total well-associated  radioactivity and has been 
subtracted. 
Results 
CD44(GP85) Cytoplasmic Domain Deletion Mutants 
and Their Expression in COS Cells 
To map the ankyrin-binding  domain in CIM4(GP85),  we 
have constructed  four mutants of CD44(GP85) (designated 
CIM4[GP85]A355, CIM4[GP85]A320, CD44[GP85]A305, 
and CD44[GP85]A292) in which various portions of the cy- 
toplasmic domain of CIM4(GP85) have been deleted from 
the carboxyl terminus (Fig.  1). Specifically,  CD44(GP85)- 
363 (the wild-type containing full length eDNA with no de- 
letion), CIM4(GP85)A355 (a mutant eDNA with 8 aa de- 
letion),  CIM4(GP85)A320  (a  mutant eDNA  with  43  aa 
deletion),  CIM4(GP85)A305  (a mutant eDNA with 58 aa 
deletion), and CD44(GP85)A292 (a mutant eDNA with 71 
aa deletion) constructs encode for proteins consisting of 363, 
355, 320, 305, and 292 aa,  respectively.  Subsequently,  the 
CD44(GP85)  wild-type  and various mutant cDNAs  were 
cloned into pcDNA I vector (Fig.  1) followed by expression 
in COS cells. 
To detect  surface  expression of CD44(GP85),  we have 
performed surface iodination of COS cells (transfected with 
CD44(GP85) wild-type and various mutant cDNAs) followed 
by Triton X-100 extraction  and sequential  WGA-Sepharose 
and anti-CIM4(GP85) column chromatographies.  Our re- 
sults clearly  indicate that the COS ceils transfected with the 
wild-type CD44(GP85)363 cDNA express a surface protein 
of 85 kD, whose molecular mass is the same as that of the 
most common hemopoietic isoform, GP85 (Fig. 2, lane 3). 
Furthermore,  we  have  found  that  the  various  truncated 
CD44(GP85) proteins  are also expressed on the surface of 
the COS cells (Fig. 2, lanes 4-7). Most importantly, the ap- 
parent molecular mass of the CD44(GP85) mutant proteins 
expressed on the COS cells appear to correspond very well 
with  the  molecular  mass  predicted  by  deletion  mutation 
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Figure 1. A schematic illustration of the in vitro mutagenesis ap- 
proach used in this study. The four cytoplasmic deletion mutants 
of CIM4(GP85)  were constructed according to the strategy de- 
scribed in the Materials and Methods. These constructs including 
CD44(GP85)363 (the wild-type containing full-length cDNA with 
no deletion), CIM4(GP85)A355 (a mutant cDNA with 8 aa dele- 
tion),  CD44(GP85)A320 (a mutant cDNA with 43 aa deletion), 
CD44(GP85)A305  (a mutant  cDNA  with  58  aa deletion),  and 
CIM4(GP85)A292 (a mutant cDNA with 71 aa deletion) were then 
subcloned into pcDNA I and transfected into COS cells to express 
proteins that encode 363, 355, 320, 305, and 292 aa, respectively. 
analysis (Figs. 1 and 2). As expected, a consistent size reduc- 
tion of CIM4(GP85) protein becomes detectable in the dele- 
tion  mutants  (e.g.,  CD44[GP85]A355  [Fig.  2,  lane  4], 
CD44[GP85]A320 [Fig. 2, lane 5], CD44[GP85]A305 [Fig. 
2, lane 6], and CD44[GP85]A292 [Fig. 2, lane 7]) which ex- 
press proteins of ,u84, 80, 78, and 76 kD, respectively. Sur- 
face expression of the CIM4(GP85) protein on COS cells 
transfected with CD44(GPg5) wild-type and mutant cDNAs 
appears to be specific since control samples (COS cells ei- 
ther untransfected [Fig. 2, lane/] or transfected with pcDNA 
I vector alone [Fig. 2, lane 2]) reveal no surface expression 
of CD44(GP85). 
In addition, the isolation procedure used in this study (i.e., 
Triton  X-100  extraction plus  sequential  WGA-Sepharose, 
anti-CD44[GP85] column chromatographies) allows us to 
obtain pure CD44(GP85) protein from COS cells transfected 
with various cDNAs.  For example, COS  ceils transfected 
with CD44(GP85)A320 cDNA reveal a single CD44(GP85) 
protein as shown by silver staining (Fig. 2, lane 8). The same 
purification procedure was used to obtain purified CD44- 
(GP85) proteins from COS cells transfected with wild-type 
and the other three truncated CD44(GP85) cDNAs (data not 
shown).  The availability of purified CD44(GP85) proteins 
from COS cells transfected with wild-type or mutant cDNAs 
has allowed us to perform in vitro ankyrin-binding assays for 
the  purpose  of  mapping  the  ankyrin-binding  domain  of 
CD44(GP85). 
Mapping the Ankyrin-binding Domain of  CD44(GP85) 
We have shown previously that the cytoplasmic domain of 
CD44(GP85)  is  involved in  the  interaction with ankyrin, 
both in vivo and in vitro (16, 37).  Several posttranslational 
modifications  appear  to  be  required  for effective CD44- 
(GP85)-ankyrin binding (12,  38, 45). In this study we have 
used an in vitro binding assay to determine the effect of the 
four cytoplasmic domain deletions on the ability of CD44- 
(GP85) to bind ankyrin in order to better define the anky- 
rin-binding domain of CD44(GP85).  Specifically, purified 
Figure 2. Expression of vari- 
ous  CD44(GP85)  proteins 
purified from COS cells trans- 
fected with wild type and mu- 
tant  cDNAs. Various CD44- 
(GP85) proteins were purified 
from  either  surface  ~25I- 
labeled  or  unlabeled  COS 
cells transfected with various 
CIM4(GP85)  constructs  by 
Triton  X-100 solubilization, 
sequential  WGA-Sepharose 
and  anti-CD44(GP85)  im- 
munoatfinity chromatography 
as  described  in  Materials 
and  Methods. The  purified 
proteins  were  analyzed  by 
SDS-PAGE followed by auto- 
radiography or silver staining. Lanes 1-7 represent autoradiograms of proteins purified from surface 12~I-labeled  COS cells. (Lane 1 ) Un- 
transfected control; (lane 2) pcDNA I vector alone; (lane 3) CD44(GP85)363; (lane 4) CD44(GP85)A358; (lane 5) CD44(GP85)A320; 
(lane 6) CD44(GP85)A305; (lane 7) CD44(GP85)A292. (lane 8) Silver staining of mutant CD44(GP85)A320 protein purified from un- 
labeled COS cells transfected with CD44(GP85)A320 cDNA. 
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with CD44(GP85) wild-type and various mutant cDNAs, 
were incubated with various concentrations  of 125I-labeled 
ankyrin under equilibrium-binding  conditions.  As shown in 
Fig. 3 A, ankyrin binds specifically to both CD44(GP85)363 
(wild-type) (Fig.  3 A,  a)  and CD44(GP85)A355  (mutant 
with an 8 aa deletion) (Fig. 3 A, b) proteins in a dose-depen- 
dent and saturable manner.  Scatchard  plot analyses of the 
equilibrium-binding  isotherms shown  in Fig.  3 A indicate 
that ankyrin binds to these proteins at a single site (Fig.  3 
B, a and b) with high affinity (an apparent  dissociation  con- 
stant [Kd] of =1 nM) (Fig.  3 B, a and b) similar  to that ob- 
tained for the mouse lymphoma GP85 protein (13). These 
results  indicate  that  the COOH-terminal  8 cytoplasmic aa 
may be deleted without affecting ankyrin binding.  An addi- 
tional deletion of the sequence between aa 320 and 355 (i.e., 
CD44[GP85]A320 [mutant  with a 43 aa deletion])  causes 
a  slight  reduction in binding  of n5I-labeled ankyrin  com- 
pared  to  the  wild-type,  CD44(GP85)363,  or the mutant, 
CD44(GP85)A355 proteins (Fig. 3 A, c). This mutant pro- 
tein also binds ankyrin  with a  slightly  lower affinity  (I~ 
=2.6 nM) (Fig.  3 B, c). These results  suggest that ankyrin- 
binding  affinity has been reduced when 43 COOH-terminal 
aa are deleted. The sequence between aa 320 and 355 (desig- 
nated as "region  1/" of the cytoplasmic domain of CD44- 
[GP85])  shares  a  great  deal of sequence homology with 
CD44 proteins from various species (Table I A; 7, 51, 55, 
65, 70 [GenBank  Acc. No. X66862]). 
Most importantly,  no ankyrin binding is detected after de- 
leting 58 aa (CD44[GP85]A305 mutant protein) or all 71 aa 
(CD44[GP85]A292 mutant protein) of the COOH-terminal 
region (Fig.  3 A, d and e). These findings indicate that the 
ankyrin-binding  domain of CIM4(GP85) must reside be- 
tween aa 305 and 355.  The  15 aa (~NGGNGTVEDRK- 
PSE32°L) sequence is designated  as the region I of the cyto- 
plasmic domain of CD44(GP85) (Table I A).  This region 
appears to share a great deal of homology with various CD44 
proteins from different species (Table I A) (7, 51, 55, 65, 70 
[GenBank Ace. No. X66862]).  Since the deletion of both re- 
gion I and 11 but not region 11 alone shows a complete loss of 
ankyrin binding,  it suggests that the region I may be an im- 
portant part of the ankyrin-binding  domain of CD44(GP85). 
To examine whether region I of the cytoplasmic domain 
of CD44(GP85) is involved in ankyrin binding, we have tested 
the ability of a synthetic  region I peptide (e.g., NGGNGT- 
VEDRKPSEL) to  bind  various cytoskeletal proteins.  As 
shown in Fig. 4 (panel/), the region I peptide binds ankyrin 
specifically and in a dose-dependent manner (Fig. 4, panel 
1 A). The binding of this peptide to ankyrin is specific since 
it does not bind other cytoskeletal proteins such as spectrin 
(Fig. 4 [panel 1 B] or fodrin (Fig. 4 [panel 1 C]). A control 
peptide (GRNETNPEGSGLDVK), containing  a scrambled 
sequence with the same amino acid composition as that of 
the synthetic region I peptide, does not bind either ankyrin 
or spectrin or fodrin (Fig. 4 [panel 2, A, B, and C]). To fur- 
ther analyze the role of region I in ankyrin binding,  we have 
used the synthetic peptide corresponding to region I to com- 
pete the binding  of pure mouse T-lymphoma  CD44(GP85) 
to ankyrin. As shown in Fig. 5 A, the synthetic peptide com- 
petes effectively with CD44(GP85) to bind ankyrin with an 
apparent  inhibition  constant  (Ki) =50  nM.  However,  the 
control peptide with the scrambled sequence does not corn- 
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Figure  3. Binding of uSI-labeled ankyrin to various  CIM4(GP85) 
proteins.  Various  concentrations  of  ~25I-labeled  ankyrin  were incu- 
bated  with  purified  CIM4(GP85)363 (the  wild-type  protein)  or  mu- 
tant  proteins  at  4°C for  5  h as  described  in  the  Materials  and  Meth- 
ods. Nonspecific  binding  was determined in presence  of 100-fold 
excess  of  unlabeled  ankyrin  and subtracted  from the  total  binding. 
Results  represent  an average  of  triplicate  determinations  from the 
same experiment.  Standard  deviation  is  less  than  5  %. (A)  Equilib- 
rium binding between  ~25I-labeled  anloyrin  and various CIM4- 
(GP85) proteins  such as CD44(GP85)363 (a),  CIM4(GP85)A355 
(b), CIM4(GP85)A320  (c),  CD44(GP85)A305  (d),  and CIM4- 
(GP85)A292 proteins  (e).  (B)  Scatchard  plot  analysis  of  the  equilib- 
rium binding  data  presented  in  Fig. 3 A for  various  CD44(GP85) 
proteins  such  as  CIM4(GP85)363 (a),  CD44(GP85)A355 (b),  and 
CEM4(GP85)A320  proteins  (c). 
pete at all  with CIM4(GP85) to bind ankyrin  (Fig.  5 A). 
Since human erythrocyte band 3 protein is a well established 
ankyrin-binding  protein  (3,  4,  20),  we  have  also  tested 
whether the region I peptide would compete with an ankyrin- 
binding  fragment (=43 kD) derived from the cytoplasmic 
domain of band 3 (40) for ankyrin binding. As shown in Fig. 
5 B, the region I peptide also competes with the 43-kD anky- 
fin-binding  domain of erythrocyte band 3 in a dose-depen- 
dent manner with an apparent inhibition  constant (K0 =200 
nM. The scrambled sequence peptide does not compete with 
the 43-kD fragment of  band 3 for ankyrin binding (Fig. 5 B). 
Lokcshwar et al. Mapping of CD44(GP85) Ankyrin-binding Domain  1103 Table I.  Sequence  Comparisons between  CD44 Isoforms and Band 3/Na+/K  + ATPase t~ Subunit Proteins 
Region I  Region H 
A" 
Mouse CD44 
Human CD44 
Rat CD44 
Hamster CD44 
Bovine CD44 
Horse CD44 
B: 
(a) 
(b) 
C: 
(a) 
(b) 
3°6N G  G  N  G  T  V  E  D  R  K  P  S  E  32°L 
3°4N  S  G  N  G  A  V  E  D  R  K  P  S  G  318L 
292N  S  G  N  G  T  V  E  D  R  K  P  S  E  306L 
~0SN  S  G  N  G  K  V  E  D  R  K  P  S  E  319L 
309N N  G  N  G  T  M  E  E  R  K  P  S  G  323L 
3°2N  N  G  I%] G  A  V  D  D  R  K  A  S  G  316L 
321NGEASKSQEMVHLVNKEPSETPDQC.TADETRNL3SSQ 
319NGEASKSQEMVHLVNKESSETPDQFXTADETRNL~53Q 
3°TNGEASKSQEMVHLVNKEPTETPDQFITADETRNL341Q 
32°NGEASKSQEMVHLVNKEPSETPDQFITADETRNL~SaQ 
32~NGEASKSQEMVHLVNKGSSETPDQFMTADETRNL35SQ 
3~TNGEASRSQEMVHLVNKESSETQDQFMTADETRNL3SZQ 
Region I 
Mouse/human  CD44  3°6N  G/S  G  N  G 
I 
Human  band 3  17aA  E  D  L  G 
T/A  V  E  D  R  K  P  S  E/G  320L 
•  "1  I  I  / 
N  L  E  G  V  K  P  A  V  i~2 
Mouse/human CD44  ~°~N G/S G N G 
•  I  I 
Human band3  ~o~  G  E G G 
T/A V  E  D  R  K  P  S  E/G  3a°L 
I  I  •  II  I  =i:  i 
T  -  E  G  H  S  P  S  G 
Mouse/human  CD44  ~°~N G/S  G  N  O 
Human Na+/K+ATPase  ....  ~  ; ~ 
(a2 subunit) 
Mouse/human CD44  ~°~N G/S G N G 
II 
Human Na+/K+ATPase  ~s  E  O N Z 
(a2 subunit) 
T/A V  E  D  R  K  P  S  -  E  -  32°L 
T/A V  E  D  R  K  P  S  E/G  3a°L 
I  III 
T  V  E  D  I AAR  640 
The sequence comparison of the ankyrin-binding domain of CD44(GP85) with similar sequences found in other ankyrin-binding proteins. The (1) indicates a perfect 
match.  The bold letters and C) indicate a conserved  substitution.  Gaps are introduced for the alignment. 
These results suggest that region I is a critical part of the an- 
kyrin-binding domain of CD44(GP85). 
Furthermore, we have constructed a fusion protein (desig- 
nated as CD45A826/CD44 [Reg.I]) (Table II) in which the 
15 aa sequence of region I of CD44(GP85) is transplanted 
onto another transmembrane protein, the truncated CD45 
molecule, CIM5A826 (64). CD45, a leukocyte common an- 
tigen (also called GP180 or T-200) has been shown to bind 
fodrin (a spectrin-like protein) but not ankyrin (15, 62, 64). 
The cDNAs  encoding various proteins  (e.g.,  CD45A826, 
CD45A826/CD44[Reg.I],  CD44[GP851363,  and  CD44- 
[GP85]A305)  are transcribed and translated in vitro using 
the TNT reticulocyte lysate system which generates ungly- 
cosylated polypeptides. We have previously shown that the 
unglycosylated precursor  of CD44(GP85)  binds  ankyrin 
equally well as the mature CD44(GP85) (43).  The polypep- 
tides synthesized by in vitro transcription and translation are 
purified by anti-CD44(GP85) or anti-CIM5 immunoaflinity 
chromatography. The CIM5A826 eDNA encodes a 105-kD 
protein corresponding  to  a  polypeptide encoding 826  aa 
(Fig. 6 A). This protein does not display any ankyrin-binding 
property (Table II). The fusion protein CD45A826/CD44- 
(Reg.I) shows a slight increase in molecular mass (=2 kD) 
compared to CD45A826 protein (Fig. 6 B).  Most impor- 
tantly, it is able to bind ankyrin (Table II) in a manner identi- 
cal to that of the unglycosylated wild-type 43-kD  CD44- 
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Figure  4.  Binding of  125I- 
labeled cytoskeletal proteins 
(e.g.,  ankyrin,  spectrin,  fo- 
drin)  to  synthetic peptides. 
Various  concentrations (20 
ne,/n~;  40 ng/nd;  80  ng/n~)  of 
nsI-labeled  cytoskdetal  pro- 
reins including  (,4)  ankyrin, 
(B) sp~m,  and (C) fodrin 
were  incubated  with  the ni- 
trocdlulosc discs coated with 
either  the  region  I  peptide 
(NGGNGTVEDRKPSEL)  or 
the  scramble  peptide  (GRN- 
ETNPEGSGL  VK)  at  4"C 
for 4 h as desfribed in the Ma- 
terials and Methods. Non-specific binding was determined in the presence of a 100-fold excess of the respective unlabeled cytoskeletal 
proteins and subtracted from the total binding. The results represent an average of duplicate determinations for each of the ligand used. 
(panel/) Binding of 125I-labeled cytoskeletal proteins to region I peptide. (panel 2) Binding of nSI-labeled cytoskeletal proteins to scram- 
ble peptide. 
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Figure  5.  Binding of  ]~I- 
labeled  mouse  T-lymphoma 
CIM4(GP85)/band 3 cytoplas- 
mic domain (43 kD fragment) 
to ankyrin, nSI-labeled CD44- 
(GP85) or band 3 cytoplasmic 
domain 43-kD fragment were 
incubated with ankyrin in the 
presence  of various  concen- 
trations of unlabeled synthetic 
region I peptide (NGGNGT- 
VEDRKPSEL) or a scrambled 
peptide (GRNETNPEGSGL- 
DVK) as described  in Mate- 
rials and Methods.  The spe- 
cific binding observed in the 
absence of any of the compet- 
ing peptides is designated as 
100%.  The results represent 
an average of duplicate deter- 
minations for each concentra- 
tion of the competing peptide 
used.  (A)  Binding of  lzsI- 
labeled CD44(GP85) to anky- 
fin (O----O, region I peptide; 
A---A,  scrambled  peptide); 
(B)  binding  of  |25I-labeled 
band  3  cytoplasmic  domain 
(43-kD fragment) to ankyrin 
(H,  region  I  peptide; 
~--4F, scrambled peptide). 
(GP85)363 protein (Fig. 6 C, and Table 1I). In addition, as 
expected the 37-kD unglycosylated CIM4(GP85)A305 pro- 
tein does not bind ankyrin (Fig. 6 D, and Table I_I). Taken 
together, these findings support the contention that the region 
I sequence (NGGNGTVEDRKPSEL) is a critical part of the 
ankyrin-binding domain of CD44(GP85). 
Effect of  Cytoplasmic Deletions of  CD44(GP85) on 
HA-mediated Binding and Adhesion in COS Cells 
Transfected with Various CD44(GP85) Constructs 
In this set of  experiments, we have attempted to correlate the 
effect of the ankyrin-binding domain with the expression of 
HA-interaction capability by COS cells transfected with vari- 
ous CIM4(GP85) constructs. Using fluorescein-HA staining 
techniques, we have found that HA-binding sites are readily 
detectable as large patched structures on the surface of COS 
cells transfected with CIM4(GP85)363 and CIM4(GP85)- 
A355 cDNAs (Fig. 7, A and B). A reduction in HA binding, 
revealed as small clusters (Fig. 7 C) is observed in COS cells 
expressing the CD44(GP85)A320 protein. Most importantly, 
we have found that cells expressing CIM4(GP85)A305 and 
CD44(GP85)A292 proteins, which lack the complete anky- 
rin-binding domain (Fig. 3 A), do not exhibit any detectable 
fluorescein-HA binding (Fig. 7, D and E). Further analysis, 
using fluorescence-conjugated anti-CD44(GP85)  antibody 
staining techniques reveals that a uniform distribution pat- 
tern (not clustered or patched) of CD44 on the surface of 
COS cells expressing CD44(GP85)A305 and CD44(GP85)- 
A292 proteins (data not shown).  This result suggests that 
ankyrin is required for the collection of CD44 into clusters 
or patches. 
The differential expression of HA-binding in COS cells 
transfected with different CD44(GP85) mutant constructs is 
further corroborated by 3H-HA-binding assays and cell ad- 
hesion to HA-coated plates. Our results indicate that the mu- 
tant  CD44(GP85)A355  protein  displays  3H-HA  binding 
(Fig. 8 B, b) and cell adhesion (Table HI) at levels compa- 
rable to those of the wild-type protein (Fig. 8, A, b and Table 
1]/).  There is  a  slight  reduction  in  both  3H-HA binding 
(Fig. 8 C, b) and cell adhesion (Table lid in COS cells ex- 
pressing the CD44(GP85)A320 protein. Most importantly, 
a  >-90%  decrease in 3H-HA binding and cell adhesion is 
observed in COS cells expressing either the CD44(GP85)- 
A305 (Fig. 8 D, b; Table HI) or CD44(GP85)A292 proteins 
Table II. Binding of ~251-labeled Ankyrin to Various Trans- 
membrane Proteins 
Ankyrin binding 
(cpm) 
TM 
c~5As26  ~  ~  1  N.D. 
TM  Reg.l 
CI~56826/CIMA(Reg.1)  [  ~  1159 +  118 
TM/Reg.1 
CD44(OP85)363  J  ~j~  1228 ± 163 
CD44(GP85)A305  ~--  _~  N.D. 
~zsI-labeled ankyrin (,~30 ng protein) was incubated with various proteins 
(e.g.,  CD45A826; CD45A826/CD44 [Reg.  I];  CD44[GP851363; and 
CD44[GP851A305)  ('~0.3 taM) as described  in the Materials  and Methods. The 
results represent  the specific  binding  and are an average  of  duplicate  determina- 
tion from  the same experiment. N.D., Not detectable. 
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transcription and translation. CD45A826, CD45A826/CD44(Reg.I), 
CD44(GP85)363, and CD44(GP85)A305 cDNAs were transcribed 
and translated in vitro and purified by immunoaflinity chromatog- 
raphy as described in the Materials and Methods. Purified proteins 
were analyzed by SDS-PAGE and fluorography. (lane A) CD45- 
A826; (lane B) CD45A826/CD44(Reg.I); (lane C) CD44(GP85)- 
363; (lane D) CD44(GP85)A305. 
(Fig. 8 E, b; Table HI). As controls, COS cells either trans- 
fected with peDNA I vector alone or untransfected were also 
analyzed and show a background level of HA-mediated bind- 
ing (data not shown) and cell adhesion to HA-coated plates 
(Table IR). To verify that the loss of HA-binding sites in the 
COS ceils transfected with certain mutants is not due to a 
failure to express CD44(GP85) on the cell surface, we have 
also quantitatively determined the expression of  CD44(GP85) 
by incubating the COS  cells with  nSI-labeled  anti-CD44- 
(GP85) antibody.  Fig.  8  shows that COS  cells transfected 
with  various  constructs  express  comparable  amounts  of 
CD44(GP85) (Fig. 8 A a, B a,  C a, D a, and E a); only a 
small reduction in CD44(GP85) expression (=15%) is ob- 
served in COS cells transfected with either CD44(GP85)- 
A320  (Fig.  8  C,  a),  CD44(GP85)A305  (Fig.  8  D,  a)  or 
CIM4(GPg5)A292 cDNAs (Fig. 8 E, a) when compared to 
the wild-type (Fig.  8 A, a) and CD44(GP85)A355 expres- 
sion (Fig. 8 B, a). Since all of these mutant proteins are ex- 
pressed on the COS cell surface (Figs. 2, 7, and 8), these re- 
suits strongly suggest that ankyrin binding to the cytoplasmic 
Figure 7.  Fluorescence staining of fluorescein-HA-labeled COS 
cells expressing various CD44(GP85) proteins. COS cells trans- 
fected  with  various  CD44(GP85)  constructs  (e.g.,  A,  CD44- 
[GP851363 eDNA; B, CIM4[GP851A355 eDNA; C, CIM4[GP85]- 
A320 eDNA; D, CD44[GP85]A305 eDNA; E, CD44[GP85]A292 
eDNA) were fixed with 2% paraformaldehyde at room temperature 
for 30 min. The fixed cells were incubated with fluorescein-conju- 
gated HA at room temperature for 30 min as described in the Mate- 
rials and Methods. 
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HA-binding and HA-mediated cell adhesion. 
Discussion 
CD44(GP85) binds extracellular matrix components such as 
HA at its NH2-terminal domain and contains an ankyrin- 
binding site within its 70 aa long COOH-terminal domain 
(38, 69, 70). It has been suggested that ankyrin binding to 
CIM4(GP85)  is involved in lymphocyte activation (8,  9). 
However,  at the present time, the relationship between the 
two functional domains, i.e., the ankyrin-binding and HA- 
mediated binding/adhesion, is not well understood. In this 
work,  we  have  identified the  ankyrin-binding domain in 
CD44(GP85).  Furthermore, we have shown that the anky- 
fin-binding domain in the cytoplasmic tail of CIM4(GP85) 
is very important for HA-binding and HA-mediated adhe- 
sion functions. 
Ankyfin is known to link various transmembrane proteins 
to actin network through interaction with spectfin or fodrin 
(a spectrin-like protein) (4, 46).  For example, in erythro- 
cytes, ankyfin connects band 3 anion exchange protein to 
spectrin (3, 4, 20). In non-erythrocytes, ankyfin is shown to 
be associated with a  number of physiologically important 
proteins including the Na+/K+  ATPase (49, 50), voltage- 
dependent (25) and amiloride-sensitive Na+ channels (57), 
inositol 1,4,5  triphosphate 0P3)  receptor (10) and CIM4- 
(GP85) (16, 37) possibly via fodrin. Among these proteins, 
the interaction between ankyfin and CIM4(GP85) may be 
considered as one of  the most well understood in non-erythro- 
cytes. Our laboratory has extensively characterized the in- 
teraction between CIM4(GP85) and ankyrin (12,  13, 16, 37, 
38, 43, 45).  However,  the aa sequence of CD44(GP85) in- 
volved in ankyrin binding has not yet been identified. 
Since the cytoplasmic domain of CD44(GP85) is relatively 
short (=70 aa) in comparison to other well characterized 
ankyfin-binding proteins (e.g., erythrocyte band 3 [39, 47], 
it offers us an excellent opportunity to map the ankyrin-hind- 
ing site(s) of CIM4[GP85]). Our deletion mutation analysis 
indicates that the ankyrin-binding domain of CIM4(GP85) 
resides in aa 305  and 355.  However,  at least two regions 
within this domain contribute to ankyrin binding. Region I, 
contains 15 aa between 305 and 320; and region II contains 
35 aa between 320 and 355 (Table I A). The region II appears 
Table III.  Cell Adhesion to HA-coated Plates 
Total specific  % of cells 
binding (epm) to  adhering 
Cell  HA-coated plates  HA-coated plates 
Control (pcDNA I alone)  0.38 + 0.05  x  105  9.2% 
CD44(GP85)363  4.11 5:0.26  x  105  100%* 
CD44(GP85)A355  4.18 + 0.14  x  103  102% 
CD44(GP85)A320  3.85 + 0.21 x  105  93.6% 
CD44(GP85)A305  0.49 5:0.02  x  10  ~  11.9% 
CD44(GP85)A292  0.44 5:0.07  x  105  10.7% 
* COS cells trlmsf~'ted with various CD44(GP85) cDNAs or with pcDNA I 
vector alone (control)  were labeled with Tran[35S]methionine.  Labeled cells 
(1.2  x  106 cpm) were incubated with HA-coated plates as described in the 
Materials and Methods. Non-specific binding was determined in the presence 
of 100 #g/ml of soluble HA and subtracted form the total binding. The results 
represent an average of triplicate determinations. The amount of specific radio- 
activity (epm) bound for cells expresssing  CD44(GP85)363 (wild-type)  protein 
is designated as 100%. 
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Figure 8.  Binding  of n5I-labeled anti-CD44(GP85) antibody and 
3H-HA to COS cells transfeeted with various CD44(GP85) con- 
structs. COS cells transfected  with various CD44(GP85) constructs 
(CIM4[GP851363 (A); CIM4[GP85]A355 (B); CIM4[GP85]A320 
(C); CD44[GP85]A305 (D) and CIM4[GP85]A292 (E) were in- 
cubated  with  two  different reagents such  as  l~I-labeled  anti- 
CD44(GP85) antibody or 3H-HA as described in the Materials 
and Methods. Non-specific  binding was determined in the presence 
of 100-fold excess of unlabeled anti-CD44(GP85) or HA and sub- 
tracted from the total binding. The binding of t2SI-labeled anti- 
CD44(GP85) antibody or 3H-HA to COS cells transfected with 
the wild-type CIM4(GP85)363 construct is designated as a control 
(100%). The results represent an average of duplicates using three 
different concentrations of each reagent (e.g.,  mI-labeled anti- 
CD44[GP85] antibody or 3H-HA). 
to be required for the high affinity ankyrin binding, since its 
deletion (e.g., CIM4(GP85)A320 protein) results in a 2-2.5- 
fold decrease in the dissociation constant for ankyrin bind- 
ing. This region is conserved in various CD44(GP85) pro- 
teins from different species (Table I A). Nevertheless, no se- 
quence homology is detected between CD44's region II and 
other ankyrin-binding proteins  (e.g.,  band 3  and Na+/K  + 
ATPase, etc.) using a Best fit program (Genetics Computer 
Group Inc., 24).  It is possible that this region contains reg- 
ulatory domains (e.g., protein kinase C-mediated phosphor- 
ylation, GTP binding, GTPase activity, etc.) responsible for 
the upregulation of CD44(GP85)-ankyrin interaction (38, 
45). Deletion of these regulatory domains could result in the 
observed reduction of high affinity binding between CD44- 
(GP85) and ankyfin. 
The deletion of both region I and II of CIM4(GP85) leads 
to a complete loss of ankyrin binding. This suggests that the 
region I (~NGGNGTVEDRKPSE320L) is required for an- 
kyrin binding. The fact that (a) the region I peptide (but not 
the scrambled peptide) binds ankyrin specifically and in a 
dose-dependent manner (Fig. 4); (b) the synthetic region I 
peptide (but not the scrambled peptide) competes effectively 
with mouse T-lymphoma CD44(GP85) for ankyrin binding 
(Fig. 5); and (c) a fusion protein expressing this sequence ac- 
quires the ability to bind ankyrin (Table ID, clearly demon- 
strates that the region I sequence must be a required part of 
the ankyrin-binding domain of CIM4(GP85). 
Since the region I peptide also competes effectively (Ki 
=200 riM) with the 43-kD ankyrin-binding fragment of hu- 
man band 3 protein, a region I-like sequence may also be 
present in band 3 protein that is required for ankyrin binding. 
Using a Best fit (Genetics Computer Group Inc., 24) pro- 
gram to compare region I and the 43-kD ankyrin-binding  do- 
Lokeshwar et al. Mapping of CD44(GP85) Ankyrin-binding Domain  1107 main of band 3 protein, we have found a sequence between 
aa 178 and 192 has limited sequence similarity  with region 
I (Table I B, a). It is interesting  to note that this band 3 se- 
quence partially overlaps with a region (between aa 174 and 
186) of band 3 that is known to be involved in ankyrin bind- 
ing (20). However, it has been suggested that the region be- 
tween aa 174 and 186 of  band 3 protein alone is not sufficient 
to account for all the high affinity interaction  between the cy- 
toplasmic domain (43-kD fragment) and ankyrin (20). After 
further sequence comparison between region I and the 43- 
kD fragment, we have found a second sequence in band 3 
(aa 203-216) that also shares some sequence similarity  with 
region I (Table I B, b). It is possible that both of these se- 
quences are necessary for the high affinity binding observed 
between the cytoplasmic domain of band 3 and ankyrin (20). 
In addition,  sequence comparison reveals two segments,  aa 
109-123 and aa 627-640 of Na+/K+-ATPase o~ subunit (an- 
other well characterized  ankyrin-binding  protein) (49, 50, 
56), that share some sequence similarity with region I (Table 
I C). The sequence between aa 627 and aa 640 appears  to 
be included in one of two ankyrin-binding  domains of Na+/ 
K+-ATPase a  subunit as shown by Devarajan et al. recently 
(23). However, at the present time no biochemical evidence 
is available to support the notion that another segment such 
as aa 1094423 of the Na+/K+-ATPase o~ subunit is required 
for ankyrin binding.  Further studies are needed to precisely 
map the ankyrin-binding  domain(s) in the Na+/K+-ATPase. 
In this manuscript,  we have presented a new mechanism 
which implicates  the cytoskeletal protein,  ankyrin,  in the 
regulation of HA-mediated functions.  There appears to be a 
strong  correlation  between the  presence of  an ankyrin-bind- 
ing domain in  the cytoplasmic tail  of  CD44(GP85)  and the 
expression  of  HA-binding and HA-mediated adhesion func- 
tions. For example,  cells expressing the mutant protein 
CIM4(GP85)A320  that lacks region II of the ankyrin- 
binding domain displays a moderate decrease in both an- 
kyrin-binding  affinity  and  HA-mediated  functions.  More 
importantly,  ceils expressing  the mutant  proteins  CD44- 
(GP85)4305 and CIM4(GP85)A292 that lack the entire an- 
kyrin-binding  domain (both region I and ID, display no an- 
kyrin binding and nearly a complete loss of HA-binding and 
HA-mediated adhesion  functions.  These findings  strongly 
imply that the intracellular  interaction  of CIM4(GP85) with 
ankyrin  is required for its adhesion functions  on the cell 
surface. 
The fact that HA-binding and HA-mediated adhesion func- 
tions can be readily inhibited by cytoskeletal drugs, such as 
cytochalasin D (a microfilament inhibitor) or W-7 (a calrnod- 
ulin inhibitor), suggests an involvement of actin and myosin- 
mediated contraction in HA-mediated functions (13). The in- 
volvement of the cytoskeleton in controlling  the exposure of 
high affinity binding  sites for hormones such as insulin and 
interleukin-2  has  also been reported previously (11, 36). 
Similar observations have also been made in other adhesion- 
related events. For example, the cytoskeleton binding domain 
within the cytoplasmic tail of the integrin  B1 subunit is in- 
volved in the formation of focal adhesion plaques (53). Fur- 
thermore,  cytoskeleton binding  is also important  for the 
function of a  number of other adhesion molecules (e.g., 
ICAM-1,  N-CAM,  and  E-eadherin)  (27).  Taken together, 
these findings strongly suggest that the binding of membrane- 
associated cytoskeletal proteins,  such as ankyrin, to the cy- 
toplasmic domain of CD44(GP85) is critically  important in 
regulating various cell-cell and cell-extracellular matrix in- 
teractions. 
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